ADC Spirogen Approach

Spirogen’s Antibody-Drug Conjugate (ADC) technology delivers extremely potent anticancer agents to cancer cells by attaching them to antibodies. Spirogen has developed highly potent warheads based on its proprietory Pyrrolobenzodiazepines (PBDs).  These PBD warheads are joined to antibodies by linkers which are stable in the blood stream but release the PBD warhead once it is safely inside the targeted cancer cells.